Expanded Access Program of Surufatinib

Neuroendocrine Tumors Clinical Trial

Official title:

An Expanded Access Program of Surufatinib for Patients With Advanced or Metastatic Neuroendocrine Tumors

Clinical Trial Details — Status: No longer available

Administrative data

• NCT number: NCT04814732
• Other study ID #: 2020-012-GLOB3
• Status: No longer available

Study information

• Verified date: April 2024
• Source: Hutchmed
• Contact: n/a
• Is FDA regulated: No
• Study type: Expanded Access

Clinical Trial Summary

This treatment protocol is intended to provide early access of surufatinib to patients with locally advanced or metastatic NETs for whom, in the opinion of their treating physician, other treatment options or surufatinib clinical trials in this indication are unsuitable. This EAP is currently available in the US only.

Description:

Prior to any assessments, all subjects must provide a signed ICF. Prior to inclusion in the program, the patients must undergo all appropriate screening procedures to check for eligibility. Once eligibility is confirmed, patients will receive treatment with surufatinib 300mg, orally (PO), daily (QD). All patients will undergo continuous monitoring for safety until the end of treatment. There is no pre-defined duration of treatment for each patient. Patients will be treated until progressive disease (as defined by treating physician), unacceptable toxicity, death, withdrawal from program, the treatment becomes commercially available, or halting of product development. A follow-up clinic visit is recommended for all patients approximately 30 days after last dose of treatment to complete the final safety assessments, as applicable.

Recruitment information / eligibility

• Status: No longer available
• Enrollment: 0
• Gender: All
• Age group: 12 Years and older

Eligibility

Inclusion Criteria:

1. Histologically or cytologically documented, well differentiated, locally advanced or metastatic NETs

2. The patient or parent/legal guardian (as appropriate) is willing and able to provide informed consent, and where required, the patient is willing to provide assent

3. =12 years of age

4. In the opinion of the patient's treating physician, other treatment options or clinical trials in this indication are unsuitable

5. Patient has adequate bone marrow and organ function

6. Urine dipstick =1+ for proteinuria or =30 mg/dL in urinalysis,

7. ECOG =2 for adult patients (=18 years of age), Karnofsky =60 for patients >16 and <18 years of age, and Lansky =60 for pediatric patients =16 years of age

8. For female patients of childbearing potential and male patients with partners of childbearing potential, agreement (by patient and partner) to use a highly effective form(s) of contraception

Exclusion Criteria:

1. Uncontrollable hypertension, as defined by local institution

2. Gastrointestinal disease or condition that the physician suspects may affect drug absorption

3. History or presence of a serious hemorrhage

4. Clinically significant cardiovascular disease

5. Brain metastases and/or spinal cord compression untreated with surgery and/or radiotherapy

6. High risk of bleeding at screening due to tumor invasion

7. Arterial thrombosis or deep venous thrombosis within 6 months prior to first dosing or thromboembolic events (including stroke and/or transient ischemic attack) within 6 months prior to first dosing

8. Received treatment with anticancer therapy, including investigational therapy, within 7 days or 5 half-lives (whichever is longer)

9. Received prior treatment with surufatinib

10. Inability to take medication orally

11. Any other clinically significant comorbidities that, in the judgment of the treating physician, could predispose the patient to safety risks

Related Conditions & MeSH terms

• Neuroendocrine Tumors

Intervention

Drug:
• Surufatinib
HMP-012

Locations

Country	Name	City	State
United States	Mercy Medical Center, Medical Oncology & Hematology	Baltimore	Maryland
United States	Roswell Park Cancer Institute	Buffalo	New York
United States	Texas Oncology - Baylor Charles A. Sammons Cancer Center	Dallas	Texas
United States	Rocky Mountain Cancer Center	Denver	Colorado
United States	Karmanos Cancer Center	Detroit	Michigan
United States	Summit Medical Group	Florham Park	New Jersey
United States	MidAmerica Cancer Care	Kansas City	Missouri
United States	Intermountain Healthcare	Murray	Utah
United States	Providence Cancer Institute Franz Clinic, Providence Health & Services	Portland	Oregon
United States	Intermountain Cancer Center	Saint George	Utah
United States	Avera Cancer Institute	Sioux Falls	South Dakota

Sponsors (1)

Lead Sponsor	Collaborator
Hutchmed

Country where clinical trial is conducted

United States,